Diphlorethohydroxycarmalol Attenuates Palmitate-Induced Hepatic Lipogenesis and Inflammation SCIE SCOPUS
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cha, S.-H. | - |
dc.contributor.author | Hwang, Y. | - |
dc.contributor.author | Heo, S.-J. | - |
dc.contributor.author | Jun, H.-S. | - |
dc.date.accessioned | 2020-12-10T07:46:09Z | - |
dc.date.available | 2020-12-10T07:46:09Z | - |
dc.date.created | 2020-10-05 | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 1660-3397 | - |
dc.identifier.uri | https://sciwatch.kiost.ac.kr/handle/2020.kiost/38582 | - |
dc.description.abstract | Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, encompassing a range of conditions caused by lipid deposition within liver cells, and is also associated with obesity and metabolic diseases. Here, we investigated the protective effects of diphlorethohydroxycarmalol (DPHC), which is a polyphenol isolated from an edible seaweed, Ishige okamurae, on palmitate-induced lipotoxicity in the liver. DPHC treatment repressed palmitate-induced cytotoxicity, triglyceride content, and lipid accumulation. DPHC prevented palmitate-induced mRNA and protein expression of SREBP (sterol regulatory element-binding protein) 1, C/EBP (CCAAT-enhancer-binding protein) alpha, ChREBP (carbohydrate-responsive element-binding protein), and FAS (fatty acid synthase). In addition, palmitate treatment reduced the expression levels of phosphorylated AMP-activated protein kinase (AMPK) and sirtuin (SIRT)1 proteins, and DPHC treatment rescued this reduction. Moreover, DPHC protected palmitate-induced liver toxicity and lipogenesis, as well as inflammation, and enhanced AMPK and SIRT1 signaling in zebrafish. These results suggest that DPHC possesses protective effects against palmitate-induced toxicity in the liver by preventing lipogenesis and inflammation. DPHC could be used as a potential therapeutic or preventive agent for fatty liver diseases. | - |
dc.description.uri | 1 | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.subject | NONALCOHOLIC FATTY LIVER | - |
dc.subject | NF-KAPPA-B | - |
dc.subject | ISHIGE-OKAMURAE | - |
dc.subject | THERAPEUTIC TARGET | - |
dc.subject | INSULIN-RESISTANCE | - |
dc.subject | OXIDATIVE STRESS | - |
dc.subject | RESVERATROL | - |
dc.subject | DISEASE | - |
dc.subject | SIRT1 | - |
dc.subject | DAMAGE | - |
dc.title | Diphlorethohydroxycarmalol Attenuates Palmitate-Induced Hepatic Lipogenesis and Inflammation | - |
dc.type | Article | - |
dc.citation.title | MARINE DRUGS | - |
dc.citation.volume | 18 | - |
dc.citation.number | 9 | - |
dc.contributor.alternativeName | 허수진 | - |
dc.identifier.bibliographicCitation | MARINE DRUGS, v.18, no.9 | - |
dc.identifier.doi | 10.3390/md18090475 | - |
dc.identifier.scopusid | 2-s2.0-85091555208 | - |
dc.identifier.wosid | 000581413500001 | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.subject.keywordPlus | NONALCOHOLIC FATTY LIVER | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | ISHIGE-OKAMURAE | - |
dc.subject.keywordPlus | THERAPEUTIC TARGET | - |
dc.subject.keywordPlus | INSULIN-RESISTANCE | - |
dc.subject.keywordPlus | OXIDATIVE STRESS | - |
dc.subject.keywordPlus | RESVERATROL | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | SIRT1 | - |
dc.subject.keywordPlus | DAMAGE | - |
dc.subject.keywordAuthor | hepatic steatosis | - |
dc.subject.keywordAuthor | lipogenesis | - |
dc.subject.keywordAuthor | seaweed | - |
dc.subject.keywordAuthor | polyphenol | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |